BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 34610112)

  • 1. Inhibiting casein kinase 2 sensitizes acute lymphoblastic leukemia cells to venetoclax via MCL1 degradation.
    Lázaro-Navarro J; Pimentel-Gutiérrez HJ; Gauert A; Hagemann AIH; Eisenschmid J; Gökbuget N; Vick B; Jeremias I; Seyfried F; Meyer LH; Debatin KM; Richer K; Bultman M; Neumann M; Hänzelmann S; Serve H; Astrahantseff K; Rieger MA; Eckert C; Baldus CD; Bastian L
    Blood Adv; 2021 Dec; 5(24):5501-5506. PubMed ID: 34610112
    [No Abstract]   [Full Text] [Related]  

  • 2. The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells.
    Li Z; He S; Look AT
    Leukemia; 2019 Jan; 33(1):262-266. PubMed ID: 30008477
    [No Abstract]   [Full Text] [Related]  

  • 3. Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.
    Teh TC; Nguyen NY; Moujalled DM; Segal D; Pomilio G; Rijal S; Jabbour A; Cummins K; Lackovic K; Blombery P; Thompson E; Ekert PG; Lessene G; Glaser SP; Huang DCS; Roberts AW; Guthridge MA; Wei AH
    Leukemia; 2018 Feb; 32(2):303-312. PubMed ID: 28751770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Leonard JT; Rowley JS; Eide CA; Traer E; Hayes-Lattin B; Loriaux M; Spurgeon SE; Druker BJ; Tyner JW; Chang BH
    Sci Transl Med; 2016 Aug; 8(354):354ra114. PubMed ID: 27582059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fatal tumor lysis syndrome in a pediatric patient with acute lymphoblastic leukemia treated with venetoclax.
    Trinder SM; Soggee J; Spragg J; Alexander D; Mitchell R; Gottardo NG; Ramachandran S
    Pediatr Blood Cancer; 2024 Mar; 71(3):e30841. PubMed ID: 38149837
    [No Abstract]   [Full Text] [Related]  

  • 6. Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal
    Prukova D; Andera L; Nahacka Z; Karolova J; Svaton M; Klanova M; Havranek O; Soukup J; Svobodova K; Zemanova Z; Tuskova D; Pokorna E; Helman K; Forsterova K; Pacheco-Blanco M; Vockova P; Berkova A; Fronkova E; Trneny M; Klener P
    Clin Cancer Res; 2019 Jul; 25(14):4455-4465. PubMed ID: 31004002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells.
    Xie S; Jiang H; Zhai XW; Wei F; Wang SD; Ding J; Chen Y
    Acta Pharmacol Sin; 2016 Nov; 37(11):1481-1489. PubMed ID: 27569395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.
    Khaw SL; Suryani S; Evans K; Richmond J; Robbins A; Kurmasheva RT; Billups CA; Erickson SW; Guo Y; Houghton PJ; Smith MA; Carol H; Roberts AW; Huang DC; Lock RB
    Blood; 2016 Sep; 128(10):1382-95. PubMed ID: 27343252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo.
    Liu F; Knight T; Su Y; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Sun L; Ge Y
    Target Oncol; 2019 Jun; 14(3):351-364. PubMed ID: 31115744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The first report of complete remission following treatment with venetoclax plus prednisone in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Zhang Y; Qian JJ; Shen YJ; Hang SJ; Jin J; Zhu HH
    Ann Hematol; 2022 May; 101(5):1141-1144. PubMed ID: 34661714
    [No Abstract]   [Full Text] [Related]  

  • 11. Potent, p53-independent induction of NOXA sensitizes MLL-rearranged B-cell acute lymphoblastic leukemia cells to venetoclax.
    Fidyt K; Pastorczak A; Cyran J; Crump NT; Goral A; Madzio J; Muchowicz A; Poprzeczko M; Domka K; Komorowski L; Winiarska M; Harman JR; Siudakowska K; Graczyk-Jarzynka A; Patkowska E; Lech-Maranda E; Mlynarski W; Golab J; Milne TA; Firczuk M
    Oncogene; 2022 Mar; 41(11):1600-1609. PubMed ID: 35091682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NOXA-mediated degradation of MCL1 and BCL2L1 causes apoptosis of daunorubicin-treated human acute myeloid leukemia cells.
    Chiou JT; Huang NC; Huang CH; Wang LJ; Lee YC; Shi YJ; Chang LS
    J Cell Physiol; 2021 Nov; 236(11):7356-7375. PubMed ID: 33982799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining epigenetic therapy with venetoclax overcomes alemtuzumab resistance in T-cell prolymphocytic leukemia. A case report of a 26-year-old man with a prior history of T-cell acute lymphoblastic leukemia and GI-T lymphoma.
    Andersen MA; Valentin R; Dissing Sjö L; Borgwardt L; Schmiegelow K; Andersen MK; Marvig RL; Yde CW; Niemann CU
    Acta Oncol; 2020 Dec; 59(12):1547-1551. PubMed ID: 32970500
    [No Abstract]   [Full Text] [Related]  

  • 14. Staurosporine and venetoclax induce the caspase-dependent proteolysis of MEF2D-fusion proteins and apoptosis in MEF2D-fusion (+) ALL cells.
    Tange N; Hayakawa F; Yasuda T; Odaira K; Yamamoto H; Hirano D; Sakai T; Terakura S; Tsuzuki S; Kiyoi H
    Biomed Pharmacother; 2020 Aug; 128():110330. PubMed ID: 32504922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting.
    Karvonen H; Perttilä R; Niininen W; Hautanen V; Barker H; Murumägi A; Heckman CA; Ungureanu D
    Oncogene; 2019 Apr; 38(17):3288-3300. PubMed ID: 30631148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells.
    Alford SE; Kothari A; Loeff FC; Eichhorn JM; Sakurikar N; Goselink HM; Saylors RL; Jedema I; Falkenburg JH; Chambers TC
    Cancer Res; 2015 Apr; 75(7):1366-75. PubMed ID: 25649768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling.
    Seyfried F; Demir S; Hörl RL; Stirnweiß FU; Ryan J; Scheffold A; Villalobos-Ortiz M; Boldrin E; Zinngrebe J; Enzenmüller S; Jenni S; Tsai YC; Bornhauser B; Fürstberger A; Kraus JM; Kestler HA; Bourquin JP; Stilgenbauer S; Letai A; Debatin KM; Meyer LH
    Cell Death Dis; 2019 Jul; 10(8):571. PubMed ID: 31358732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility of the Combination of Venetoclax and Asparaginase-based Chemotherapy for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.
    El-Cheikh J; Moukalled NM; El Darsa H; Massoud R; Kanj SS; Mahfouz R; Bazarbachi A
    Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):e441-e444. PubMed ID: 30166258
    [No Abstract]   [Full Text] [Related]  

  • 19. Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment.
    Chen X; Glytsou C; Zhou H; Narang S; Reyna DE; Lopez A; Sakellaropoulos T; Gong Y; Kloetgen A; Yap YS; Wang E; Gavathiotis E; Tsirigos A; Tibes R; Aifantis I
    Cancer Discov; 2019 Jul; 9(7):890-909. PubMed ID: 31048321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Application of Pan-AKT Inhibitor MK-2206 and BCL-2 Antagonist Venetoclax in B-Cell Precursor Acute Lymphoblastic Leukemia.
    Richter A; Fischer E; Holz C; Schulze J; Lange S; Sekora A; Knuebel G; Henze L; Roolf C; Murua Escobar H; Junghanss C
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.